# overview
The discovery of novel antibiotics which have unique targets to inhibit the growth of microorganisms will minimize the suffering of those who are desperately in need of alternatives to currently available antibiotics. The competition for resources by microorganisms has led to their ability to make a wide variety of natural products that can inhibit the growth of their competitors. These antimicrobial compounds provide the best opportunity to alleviate the pain and suffering caused by infectious diseases. My research program encompasses the isolation, identification, and the development of novel antimicrobials as therapeutics. A biotechnology company named Sano Chemicals was established to promote the commercialization of technology generated from my research laboratory at Texas A&M University.

# keywords[]
2.2 Factors Relating To The Physical Environment

# publications[].label
Evolution of Lantibiotic Salivaricins: New Weapons to Fight Infectious Diseases.

# publications[].label
Novel Antiparasitic Activity of the Antifungal Lead Occidiofungin.

# publications[].label
Identification of biological pathways that mediate fungal response to occidiofungin exposure

# publications[].label
Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and Stability.

# publications[].label
Draft Genome Sequence of the Lantibiotic-Producing Strain Streptococcus salivarius HS0302.

# publications[].label
Modified lantibiotics and methods of making and using the modified lantibiotics

# publications[].label
Engineering the production of a conformational variant of occidiofungin that has enhanced inhibitory activity against fungal species

# publications[].label
Modified lantibiotics and methods of making and using the modified lantibiotics

# publications[].label
Efficacious Analogs of the Lantibiotic Mutacin 1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection.

# publications[].label
Occidiofungin formations and uses thereof

# publications[].label
Fluorescence In Situ Hybridization Probe Validation for Clinical Use.

# publications[].label
Variants of the lantibiotic MU1140 and other lantibiotics with improved pharmacological properties and structural features

# publications[].label
Formulation, Pharmacological Evaluation, and Efficacy Studies of Occidiofungin, a Novel Antifungal.

# publications[].label
Drug discovery through the isolation of natural products from Burkholderia.

# publications[].label
A Novel Actin Binding Drug with In Vivo Efficacy.

# publications[].label
Improving the attrition rate of Lanthipeptide discovery for commercial applications.

# publications[].label
Covalent Structure and Bioactivity of the Type AII Lantibiotic Salivaricin A2.

# streetAddress
Texas A&M University; Biology; 3258 TAMU